Background Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy
are brain disorders characterised by intracellular α-synuclein deposits. We aimed to assess …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

The causative agent of coronavirus disease 2019 (COVID-19) is the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). For many viruses, tissue tropism is determined by …

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about
the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in …

Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and
may be a harbinger of dementia. In view of its importance, the Movement Disorder Society …

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational,
international, multi-center study designed to identify PD progression biomarkers both to improve …

To identify rare causal variants in late-onset Parkinson disease (PD), we investigated an
Austrian family with 16 affected individuals by exome sequencing. We found a missense …

… Brit Mollenhauer contributed to the conception and execution of the research project, wrote
… Brit Mollenhauer has received honoraria from GlaxoSmithKline and Orion Pharma, grants …

Background Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s
disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is …

Background Aggregated α-synuclein plays an important role in Parkinson’s disease
pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is …